Harvard Bioscience, Inc.
corporate_fare Company Profile
Harvard Bioscience, Inc. (NASDAQ:HBIO) is a publicly traded company in the Industrial Applications And Services sector. Wiseek has independently scored 24 items for HBIO at importance 7 or higher on its 1–10 market-impact scale.
Recent high-impact activity:
- Shareholders to Vote on Reverse Stock Split to Maintain Nasdaq Listing
- Harvard Bioscience Registers 9.5M Shares for Resale by Securityholders, Creating Significant Market Overhang
- Harvard Bioscience Announces Major Manufacturing Consolidation for $4M Annual Savings
- Harvard Bioscience Seeks Shareholder Approval for Reverse Stock Split to Avoid Nasdaq Delisting
Financial Snapshot
Fiscal year ended December 31, 2025
Revenue
$86.55M
Net Income
-$56.7M
Diluted EPS
-$1.28
Op. Cash Flow
$6.73M
Free Cash Flow
$5.47M
Gross Profit
$49.91M
Operating Income
-$48.58M
Cash & Equivalents
$8.61M
Total Debt
$35.87M
Debt / Equity
2.61×
Net Margin
-65.5%
Shares Outstanding
44.72M sh
Source: 10-K · filed 2026-03-13 · accession 0001171843-26-001548
show_chartPrice Chart
Loading chart...
feed HBIO - Filings & News (Page 2)
HBIO
Jan 30, 2026, 5:15 PM EST
Price at Filing:
$0.4901
Real-time Price:
$8.00
Change:
Reverse Stock Split
Market Cap:
$36.418M
HBIO
Jan 30, 2026, 5:02 PM EST
Price at Filing:
$0.4901
Real-time Price:
$8.00
Change:
Reverse Stock Split
Market Cap:
$36.418M
HBIO
Jan 29, 2026, 4:30 PM EST
Price at Filing:
$0.5341
Real-time Price:
$8.00
Change:
Reverse Stock Split
Market Cap:
$36.418M
HBIO
Jan 20, 2026, 5:04 PM EST
Price at Filing:
$0.5821
Real-time Price:
$8.00
Change:
Reverse Stock Split
Market Cap:
$36.418M